Compounded Tirzepatide vs Zepbound Compared

Compounded tirzepatide and Zepbound contain the same active ingredient. The differences are FDA status, pricing, formulation and how you access each. Zepbound is FDA-approved at $1,499 per month. Compounded tirzepatide from BiltRx is $129 per month; from Arc-1, $199.99 to $399.99. This comparison covers what those differences mean for patients making a purchasing decision in 2026.

Key Differences at a Glance

FDA Approval Status

This is the most significant regulatory difference and the one that matters most from a safety and legal perspective.

Zepbound Is FDA-Approved

Zepbound went through the full FDA approval process, including Phase 3 clinical trials (the SURMOUNT program) that enrolled thousands of participants. The FDA reviewed manufacturing quality, safety data, efficacy data and labeling before granting approval. Eli Lilly manufactures Zepbound under current Good Manufacturing Practice (cGMP) regulations, with FDA inspections of production facilities.

Compounded Tirzepatide Is Not FDA-Approved

The FDA does not review compounded drugs for safety, effectiveness or manufacturing quality. Compounded tirzepatide is prepared by state-licensed 503A pharmacies under state board of pharmacy oversight. The ingredient is the same, but the manufacturing process, quality controls and regulatory accountability differ. Compounded tirzepatide has not been tested in clinical trials.

Pricing Comparison

Without insurance, compounded tirzepatide is 73-91% cheaper than Zepbound. With insurance and a manufacturer savings card, Zepbound can drop to approximately $25 per month, which is cheaper than any compounded option. The catch: not everyone qualifies for the savings card, and not all insurance plans cover Zepbound.

Formulation and Dosing

The delivery format and dosing flexibility differ between compounded and brand-name products.

Zepbound: Fixed-Dose Auto-Injector

Zepbound comes in pre-filled, single-use auto-injector pens at fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The patient does not draw from a vial or handle syringes. The device is designed for ease of use. Dose changes mean switching to a different pen strength, which the provider prescribes.

Compounded: Variable Concentration Vials

Compounded tirzepatide comes in multi-dose vials. The patient draws the prescribed volume using a syringe and needle. BiltRx does not publish its concentration. Arc-1 compounds at 10 mg/mL. This format requires more handling skill than an auto-injector but allows for more flexible dosing. Your provider prescribes the exact volume per injection.

Access and Availability

Insurance and Zepbound

Zepbound may be covered by commercial insurance for the weight-management indication, though many plans require prior authorization or step therapy. Mounjaro (same drug, diabetes indication) has broader coverage. If your insurance covers Zepbound with a savings card, your monthly cost can be as low as $25, making it cheaper than compounded options.

Compounded Without Insurance

Compounded tirzepatide is typically not covered by insurance. The entire cost is out of pocket. For patients without insurance coverage for brand-name tirzepatide, compounded offers a substantially lower price point. BiltRx at $129 per month is the most affordable published option among providers we verified.

Quality and Oversight

FDA Oversight of Zepbound

Eli Lilly manufactures Zepbound under cGMP regulations with FDA oversight. Batch testing, stability testing, sterility verification and potency confirmation are all part of the manufacturing process. The FDA inspects production facilities and can enforce compliance through warning letters, recalls and other regulatory actions.

503A Pharmacy Oversight of Compounded

503A compounding pharmacies are primarily regulated by their state board of pharmacy. They must follow USP standards for sterile compounding (USP 797). However, they are not subject to FDA cGMP requirements or routine FDA inspections in the same way that manufacturers of FDA-approved drugs are. The level of quality oversight is different, not absent, but different.